[ad_1]
The State Institute for Drug Control (ŠÚKL) ordered the withdrawal from the Slovak market of drugs containing the active substance valsartan.
The decision concerns all batches of Vapress, Vasopentol, Valzap and Valsartan Actavis The reason for this is the suspicion of the presence of undeclared impurities in the active substance. They are used to treat high blood pressure, symptomatic heart failure and for treatment after a recent heart attack
"As patients do not take acute risk, abrupt arrest treatment is not recommended However, it is essential that these patients visit their GP within one month, who will prescribe another appropriate treatment, " reports SUKL. Several therapeutic remedies are available on the Slovak market, the treatment of patients is not compromised
The drugs are relocated to pan-European level and the European Medicines Agency and the European Agency for the Management of quality are involved in reducing quality. In addition to other drugs containing the active substance valsartan, the Authority will consider other drugs containing other sartanas having a comparable chemical structure in the coming days
[ad_2]
Source link
